Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
ID06778122

A Series of N-of-1 Randomised, Adaptive, Blinded, Placebo-Controlled Trials of Overnight In-Bedroom Air Filtration as Adjuvant Treatment in Reducing Inflammatory Biomarkers Among Survivors of Adult-Onset Cancer With Elevated C-Reactive Protein

Led by University College, London · Updated on 2026-03-27

10

Participants Needed

3

Research Sites

N/A

Total Duration

On this page

Sponsors

U

University College, London

Lead Sponsor

I

IQAir AG

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating whether using a portable air filtration system overnight in bedrooms can reduce inflammation and heart-related biomarkers in adult cancer survivors at high risk for cardiovascular problems. The study focuses on individuals living in urban areas of Valencia, Spain, where air pollution levels exceed international safety limits. This trial uses a series of personalized randomized experiments (N-of-1 trials) to study the impact of filtered air on blood markers like C-reactive protein (CRP). Participants will undergo three treatment cycles during the blinded phase, each lasting 14 days with filtered air and 14 days with sham (unfiltered) air using the same device. The air filtration runs nightly for at least 7 hours between 10:00 p.m. and 10:00 a.m. If no meaningful reduction in CRP is observed after these cycles, participants enter an open-label phase with a 14-day no-treatment period followed by 14 days of continuous filtered air both day and night. The device uses HyperHEPA technology and dose adjustments are allowed for noise concerns. Throughout the study, participants will provide blood samples at baseline and on days 7 and 14 of each period to measure CRP and other biomarkers related to inflammation and cardiovascular health. Blood pressure readings will also be taken at these times. Air quality inside and outside the home will be continuously monitored. Participants will complete weekly questionnaires about exercise, diet, sleep quality, and daily activity patterns. The study lasts 4 to 12 weeks depending on response, with safety and adherence closely observed.

CONDITIONS

Brief Title

In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult-onset cancer survivors diagnosed with breast, colon, colorectal, rectum, prostate, non-small lung, Hodgkin lymphoma, non-Hodgkin lymphoma, chronic lymphoid leukemia, or chronic myeloid leukemia.
  • Aged 18 to 75 years at cancer diagnosis.
  • People of all genders and racial/ethnic backgrounds.
  • Non-smokers for at least the past 12 months.
  • No evidence of metastatic disease.
  • Evidence of complete remission after treatment.
  • Completed definitive cancer treatment at least 12 months prior.
  • Maintenance therapy allowed if stable and ongoing during trial.
  • High inflammatory cardiac risk with CRP ≥3 to <10 mg/L or ≥10 mg/L if acute inflammation is ruled out.
  • Stable hypertension if applicable: no medication changes in prior 30 days, systolic BP <160 mm Hg.
  • Controlled and stable chronic medical conditions allowed.
  • Routine prescribed medications continued during trial.
  • Living in specified highly polluted urban areas of Valencia.
  • Permanent residence in usual home for at least 3 months prior with no plans to move during trial.
  • Living in a non-smoking household.
  • Internet connection (Wi-Fi) at home.
  • Signed informed consent prior to study procedures.
Not Eligible

You will not qualify if you...

  • Recently diagnosed with cancer or plans for cancer therapy or surgery during trial.
  • Metastatic disease.
  • Planned new medication prescription during trial.
  • Uncontrolled hypertension: average systolic BP >160 mmHg over any 10-day period.
  • History of uncontrolled or unstable chronic disease within 6 months.
  • Psychiatric illness limiting compliance or informed consent.
  • Chronic or recurrent infectious diseases or immunocompromised state.
  • Alcohol or substance abuse in past 12 months.
  • Shift workers with schedules outside 07:00 a.m. to 10:00 p.m.
  • Plans to move from usual home during trial.
  • Unwillingness to spend at least 7 hours overnight in bedroom.
  • Pre-existing air filtration system improving household air quality.
  • Unwilling to give consent.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - Up to 4 weeks

Participants are screened for eligibility to participate in the trial.

Up to 2 home visits for blood microsampling to measure CRP levels

Treatment

Duration - Between 4 and 12 weeks depending on the number of treatment sets completed

Participants undergo a series of up to three 14-day treatment sets with either active or sham air filtration nightly in the bedroom during sleep hours, randomized and blinded. This crossover phase aims to reduce inflammatory biomarkers.

Participants use air purifiers nightly for at least 7 consecutive hours within a 10:00 p.m. to 10:00 a.m. window; biomarker measurements collected at baseline, day 7 and day 14 of each period

Wash-out Period

Duration - 14 days

A 2-week wash-out period follows the last blinded treatment set to allow any treatment effects to subside before further intervention.

No intervention during this period

Open-label Treatment

Duration - 28 days

Participants who do not achieve clinically meaningful changes after the blinded phase receive 14 days without treatment followed by 14 days of continuous nightly and daily active air filtration in the bedroom at home.

Continuous operation of air purifier 24 hours/day in bedroom for 14 days; participants asked to remain in bedroom as much as possible and keep an activity log

Trial Site Locations

Total: 3 locations

1

Gil y Morte Primary Care Practice

Valencia, Spain

Actively Recruiting

2

Mallilla Primary Care Practice

Valencia, Spain

Actively Recruiting

3

Russafa Primary Care Practice

Valencia, Spain

Actively Recruiting

Loading map...

Research Team

E

Eva Hernandez-Garcia

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

TREATMENT

Number of Arms

4

Similar Trials

A Smart Phone Application to Improve Adoption of the 2024 Ki...

Chronic Kidney Disease

Actively Recruiting

2 locations

Intensive Blood Pressure Control During Cardiotoxic Breast C...

Breast Cancer

Actively Recruiting

7 locations

Phase 2a, Proof-Of-Concept, 8-Week, Randomized, Single-Blind...

Cancer Survivors

Actively Recruiting

2 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here